Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jul 11:10:2255-62.
doi: 10.2147/DDDT.S91441. eCollection 2016.

An appraisal of golimumab in the treatment of severe, active nonradiographic axial spondyloarthritis

Julien Paccou  1 , René-Marc Flipo  1
Affiliations
Review

An appraisal of golimumab in the treatment of severe, active nonradiographic axial spondyloarthritis

Julien Paccou et al. Drug Des Devel Ther. .

Abstract

Golimumab (Simponi(®)) is a fully human tumor necrosis factor α inhibitor (TNFi) antibody administered subcutaneously. In the European Union, golimumab is indicated for the treatment of adults with severe, active axial spondyloarthritis (axSpA), which includes both ankylosing spondylitis (AS) and nonradiographic axSpA (nr-axSpA). In the US, it is indicated for the treatment of adults with active AS only. This article reviews the efficacy and tolerability of golimumab in nr-axSpA patients compared to other TNFi agents (adalimumab, infliximab, etanercept, and certolizumab pegol). In one ongoing, well-designed controlled study (GO-AHEAD), data at 16 weeks showed that treatment with golimumab (50 mg every 4 weeks) was effective in improving the clinical signs and symptoms of disease in nr-axSpA patients. In addition, 16 weeks of treatment with golimumab reduced inflammation in the sacroiliac joints and spine in patients with nr-axSpA. Moreover, objective evidence of active inflammation at baseline, such as a positive magnetic resonance imaging scan and/or an elevated CRP level, was a good predictor of treatment response to golimumab. Golimumab was generally well tolerated in this study, with a tolerability profile consistent with that seen in previous clinical trials for other indications. Although additional long-term data are needed, current evidence indicates that golimumab is an effective option for the treatment of nr-axSpA. However, in the absence of comparative head-to-head trials, there is no recommended hierarchy for the first prescription of a TNFi agent for the treatment of either nr-axSpA or AS.

Keywords: ankylosing spondylitis; axial spondyloarthritis; golimumab; nonradiographic axial spondyloarthritis; therapy; tumor necrosis factor α inhibitor.

PubMed Disclaimer

Figures

Figure 1
Figure 1
ASAS40 response in nr-axSpA patients after 12 (or 16) weeks of treatment with TNF-blocking agents. Note: Different studies, no head-to-head comparison. Abbreviations: ADA, adalimumab; ASAS, Assessment in Spondyloarthritis International Society; CZP, certolizumab; ETA, etanercept; GOL, golimumab; IFX, infliximab; nr-axSpA, nonradiographic axial spondyloarthritis; TNF, tumor necrosis factor.
See this image and copyright information in PMC

References

    1. Rudwaleit M, Landewé R, van der Heijde D, et al. The development of assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis. 2009;68:770–776. - PubMed
    1. Rudwaleit M, van der Heijde D, Landewé R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70:25–31. - PubMed
    1. Sieper J, van der Heijde D. Non-radiographic axial spondyloarthritis: new definition of an old disease? Arthritis Rheum. 2013;65:543–551. - PubMed
    1. Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondy-loarthritis. Arthritis Rheumatol. 2016;68:282–298. - PMC - PubMed
    1. Deodhar A, Reveille JD, van den Bosch F, et al. The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the assessment of SpondyloArthritis international society in response to the US Food and Drug Administration’s comments and concerns. Arthritis Rheumatol. 2014;66:2649–2656. - PubMed

MeSH terms

Substances